The Journal of Gene Medicine · 2021 · 11 citations · 22 references
Life SciencesMolecular BiologyOncologyApoptosisGene ExpressionMolecular OncologyGlioblastomaMicrorna BiologyMicrorna-mediated RegulationNoncoding Rna In CancerRna InterferenceTumor Suppressor GenesAntisense RnasCell InvasionCell Migration InvasionLuciferase Reporter AssaysLuciferase ReportersMicrorna In CancerShort Hairpin Ribonucleic AcidsShort Hairpin Rna
BACKGROUND: Although cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1) is upregulated in glioma, its function and potential mechanism in glioma remain unclear. METHODS: CDKN2B-AS1 level in glioma tissues and cell lines LN229, U251, and U87 was measured by qRT-PCR. Loss-of-function assays using short hairpin RNA for CDKN2B-AS1 (sh-CDKN2B-AS1) were performed to evaluate the effect of CDKN2B-AS1 on cell invasion, migration, proliferation, and apoptosis. The relationship among CDKN2B-AS1, miR-199a-5p, and DDR1 was determined by bioinformatics analysis and luciferase reporter assay. Rescue experiments were conducted to explore the function of CDKN2B-AS1 and miR-199a-5p in glioma. An in vivo animal model of lentivirally transduced U87 glioma xenografts in mice was established to confirm the role of CDKN2B-AS1. RESULTS: CDKN2B-AS1 is significantly upregulated in glioma tissues and cell lines. CDKN2B-AS1 knockdown significantly inhibits cell proliferation, invasion, and migration, while promoting apoptosis of glioma cell lines U251 and U87. Further, a miR-199a-5p inhibitor attenuates the inhibitory effects of sh-CDKN2B-AS1 on these cell phenotypes. CDKN2B-AS1 positively regulates DDR1 expression by directly sponging miR-199a-5p. Moreover, CDKN2B-AS1 knockdown efficiently inhibits U87 tumor xenograft growth in mice. CONCLUSION: Our study reveals that CDKN2B-AS1 promotes glioma development by regulating the miR-199a-5p/DDR1 axis, suggesting that this lncRNA might be a potential therapeutic target.
22
Identification of expressed genes characterizing long-term survival in malignant glioma patients
Ryuya Yamanaka, Tokuzo Arao, Naoki Yajima et al. · Oncogene · 2006 · 106 citations